Breast cancer ranks first among female malignant tumors, while triple-negative breast cancer (TNBC) lacks targeted treatment methods and is not satisfied with the current treatment situation because of its high heterogeneity and no expression of related receptors. With the research on tumor immunotherapy in recent years, the drugs targeting programmed cell death protein-1/programmed cell death-ligand 1 (PD-1/PD-L1) are increasingly being applied to TNBC patients. The PD-1/PD-L1 inhibitors combined with chemotherapy, targeted therapy, radiotherapy, oncolytic viruses, etc. could further improve the therapeutic effects, providing new treatment strategies for TNBC patients. This review summarized the combination therapy based on PD-1/PD-L1 inhibitors in TNBC patients, in order to provide reference for clinical treatment of TNBC patients.

Triple-negative breast cancer; Immunotherapy; Programmed cell death protein-1 inhibitor; Programmed cell death-ligand 1 inhibitor; Combination therapy